|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for US Patent 5,808,146 (Amino Acid Analog Radiolabeled with Iodine/Fluorine/Bromine): What the Claim Language Covers and How Broad the Patent Estate Is
US Patent 5,808,146 claims a family of amino-acid analogs defined by a Markush-style general structure with (i) substituent permutations for R1, (ii) ring/chain-forming constraints, and (iii) a radioisotope substitution at X restricted to ^18F, ^123I, ^125I, ^131I, ^75Br, ^76Br, ^77Br, or ^82Br. The practical scope is driven by how the dependent claims lock in specific parameter combinations (x, y, z, q, m, n, j) and by whether the “cyclic” embodiments are required or optional in each claim.
Below is a structured claim-by-claim scope map, followed by a patent landscape read-through for this specific patent number.
What is claimed in US Patent 5,808,146 and what structure governs scope?
Core answer: Claim 1 is a structural Markush claim for a radiolabeled amino acid analog defined by a general formula (Structure shown in the claims) plus constraints that determine whether the analog is formed as a specific scaffold (the claim includes a condition that “such that … is formed”), and the radiolabeling atom X is limited to a fixed set of radiohalogens including ^18F and multiple iodine isotopes.
Claim 1: the “master” Markush parameters
Claim 1 requires an amino acid analog having a general structure “##STR20##” with:
- R1 is one of:
- X
- X--CH═CH--
- or R3 (with additional constraints in the subsequent variables)
- R2 is H, or R3 if R1 is R3
- The claim then constrains a formation pathway/structure via:
- “such that ##STR22## is formed where…”
- The enumerated variables include:
- x = 0 or 1
- y = 1 or 2
- z = 1, 2, 3, or 4, with a constraint z > y if y = 2
- q = 1 or 0 with rules tied to other indices (the claim ties q to n/j in specific ways)
- n = 1 or 2, with a rule “but 0 if m is 0” (as written in the claim excerpt)
- j = 0 or 1
- m = 0 or 1 (as written)
- X is radiohalogen from a closed list: ^18F, ^123I, ^125I, ^131I, ^75Br, ^76Br, ^77Br, or ^82Br
Scope effect of the parameter set: Even without decoding every subscript’s chemistry from the image placeholders, Claim 1 is clearly broad across:
- multiple scaffold variants (x, y, z),
- multiple linkage regimes (through R1 options including “X--CH═CH--”),
- multiple radionuclide substitutions (closed list but eight isotopes total),
- multiple topological states (cyclic vs non-cyclic is explicitly used in dependent claims).
Claim 2: tightens substitution pattern
Claim 2 is Claim 1 with:
- “wherein R1 and R2 = R3”
This restricts to embodiments where the substituents collapse into a specific relationship (R1 is not “X” or “X--CH═CH--” but instead equals R3; R2 also equals R3). Practically, that removes some of the broader R1 cases and picks a narrower chemical sub-family.
Claim 3 through Claim 5: “cyclic compound” corridor
- Claim 3: “A cyclic compound according to claim 1 where in x is 0, y is 1, z is 2, q is 1, m is 0, and j is 0.”
- Claim 4: depends on Claim 3 and limits X to ^18F or ^123I
- Claim 5: depends on Claim 3 and limits X to ^18F
Scope effect: These claims are narrow but valuable. If the commercially marketed candidates use the same cyclic scaffold with ^18F or ^123I substitution, they land squarely in the dependent claim capture.
Claims 6 through 7 and Claims 10 through 17 and Claims 18 through 23: enumerated “bracketed” embodiments
Claims 6, 10, 12, 14, 16, 18, 21 each contain a dense set of constrained parameter values and then select isotopes.
From the claim text provided, the pattern is consistent:
- the compound is constrained by selecting exact combinations of x / y / z / q / m / n / j,
- and then X is set to either:
- “^18F, or ^123I” (two-isotope capture), or
- “^18F” only,
- “^123I” only.
What this does legally: This creates many separately supported embodiments. That improves enforceability against a defendant if they copy any one of those scaffold+radionuclide permutations, because infringement can be established against at least one dependent claim depending on the exact radiospecific substitution and scaffold configuration.
Key examples as written:
- Claim 6: Claim 1 where:
- R1 = R2 = R3
- x is 0 or 1
- y is 2
- z is 4
- q is 1
- m and j are each 0
- X is ^18F or ^123I
- Claim 7: depends on Claim 6, then:
- Claim 10: Claim 1 where:
- R1 = R2 = R3
- x is 0
- y is 1
- z is 2
- q is 0
- m is 1
- n is 1
- j is 0
- X is ^18F or ^123I
- Claim 12: Claim 1 where:
- R1 = R2 = R3
- x is 1
- y is 1
- z is 1
- q is 0
- m and j are 0
- X is ^18F or ^123I
- Claim 14: Claim 1 where:
- R1 = R2 = R3
- x is 0
- y is 1
- z is 2
- q is 1
- m is 1
- n is 1
- j is 1
- X is ^18F or ^123I
- Claim 16: Claim 1 where:
- R1 = R2 = R3
- x is 0
- y is 1
- z is 2
- q is 0
- m is 0
- j is 1
- X is ^18F or ^123I
- Claim 18: Claim 1 where:
- R1 = R2 = R3
- x is 0 or 1
- y is 2
- z is 4
- q is 1
- m is 1
- n is 1
- j is 1
- X is ^18F or ^123I
- Claim 21: Claim 1 where:
- R1 = R2 = R3
- x is 0 or 1
- y is 2
- z is 4
- q is 0
- m is 0
- j is 1
- X is ^18F or ^123I
And the dependent “single-isotope” claimlets then lock X:
- Claims 8–9: Claim 8 is “Claim 8 wherein x is 0 and X is ^123I” and Claim 9 is “Claim 6 wherein x is 1 and X is ^123I” (based on the numbering as excerpted).
- Claims 11, 13, 15, 17, 19, 20, 22, 23: each narrows to a single isotope at that specific parameter combination.
Scope effect: This is a typical radiochemistry IP strategy: keep the master structure broad, then carve out enforceable “sweet spots” for the most commercially used isotopes (especially ^18F and ^123I, sometimes as dual-capture).
Claim 24: a second branch when R1 differs from R3
-
Claim 24: “A compound of claim 1 wherein R1 and R2 ≠ R3.”
This opens a contrasting chemical sub-family relative to the R1=R2=R3 path in many dependent claims. It indicates Claim 1 is not limited to the R1=R3 topology.
-
Claim 25: depends on Claim 24 and sets X = ^18F.
Scope effect: Claim 25 is a clean capture for at least one ^18F embodiment in the non-R3 branch. It is narrower than Claim 1 but more targeted for enforcement.
Claims 26–27: specific R1 definition with unsaturated side-chain
- Claim 26: “wherein R1 is X--CH═CH--, R2 is H, y is 1 and z is 2.”
- Claim 27: depends on Claim 26 and sets X = ^123I.
Scope effect: This is a very particular substitution and double-bond pattern. If competitors use that “X--CH═CH--” motif with the y/z scaffold, Claim 27 gives a narrower infringement hook.
How broad is Claim 1 vs the dependent claims for infringement risk?
Featured-snippet answer: Claim 1 covers any amino acid analog within the Markush structure whose scaffold indices (x, y, z, q, m, n, j) fall within the enumerated ranges and whose radiolabel atom X is one of eight specified radioisotopes. Dependent claims narrow to particular scaffold index combinations and often narrow X to ^18F and/or ^123I (with some to a single isotope).
Breach points competitors must match
A product infringes only if it matches:
- The amino-acid analog scaffold defined by the Markush variables.
- The relationships among R1/R2/R3 (including special conditions like “R1 is X” or “R1 is X--CH═CH--” or “R1 is R3”).
- The precise index values (x, y, z, q, m, n, j).
- The radiohalogen substitution at X.
Translation to chemical design space
- If a competitor uses the same scaffold and just swaps isotopes outside the list (e.g., other iodine isotopes not listed, or non-halogen labels), Claim 1 does not cover.
- If a competitor uses ^18F or ^123I but changes the scaffold index values outside the defined combinations, dependent claims may not read.
- Claim 1 is broad enough to capture multiple variants, but enforceability tends to concentrate on the parameter-combinations that align with actual chemistry and radiolabel workflows.
What does the patent landscape look like for US 5,808,146 (expiration, exclusivity, and related IP)?
Data integrity constraint: The user provided claim text but no bibliographic metadata (filing date, issue date, assignee, continuation family, continuations/case numbers), and no Orange Book or litigation docket information. Without those, a complete landscape that includes expiration dates, regulatory exclusivity overlap, and related family patents cannot be produced accurately for this specific US patent number.
Therefore: No landscape timeline, “what patents cover the same compounds,” or “what generics/biosimilars are at risk” can be completed with the level of precision required for business decisions.
How strong is the claim estate for enforceability (based only on the provided claim set)?
Strength drivers visible in the claim text
- Closed radionuclide list: Eight isotopes are enumerated. This creates clearer boundaries for claim construction (less ambiguity than an open “radiohalogen” class).
- Multiple independent-to-dependent capture paths: Claim 1 is broad, then dependent claims provide many specific “lanes” of infringement.
- Parameter constraints provide redundancy: Many dependent embodiments cover different index combinations, increasing the chance that an accused compound aligns with at least one set.
Potential vulnerability points visible in the claim text
- Heavy dependence on variable-index matching: Many parameters must line up exactly. If claim construction narrows the meaning of the indices relative to how competitors implement their scaffolds, infringement may fail for some embodiments even if the overall concept is similar.
- Structural definitions rely on claim-drawn placeholders: The excerpt uses image placeholders for the structural formulae (“##STR20##” etc.). Without the exact definitions from the published patent specification and drawings, the practical claim-to-structure mapping is not fully operational from the excerpt alone.
Key Takeaways
- US 5,808,146 is built around a Markush structural claim (Claim 1) for radiolabeled amino acid analogs, with X limited to ^18F, ^123I, ^125I, ^131I, ^75Br, ^76Br, ^77Br, or ^82Br.
- The estate is enforceability-oriented: many dependent claims lock in specific scaffold index combinations (x, y, z, q, m, n, j) and frequently narrow X to ^18F or ^123I (and sometimes to a single isotope).
- There are at least two chemical branching concepts: embodiments with R1/R2 = R3 and embodiments with R1 and R2 ≠ R3, plus a dedicated branch for R1 = X--CH═CH-- with ^123I.
- A complete “patent landscape” (expiration, related filings, Orange Book status, litigation/settlement, and generic entry risks) cannot be produced from the provided excerpt alone.
FAQs
-
Does US 5,808,146 cover radiolabeled amino acid analogs with any radioisotope, or only specific ones?
The claims limit X to a closed list including ^18F and multiple iodines plus bromines.
-
What is the main infringement requirement in Claim 1?
The accused compound must match the Markush scaffold variables plus the R1/R2/R3 relationships and have X equal to one of the enumerated isotopes.
-
Do dependent claims primarily protect ^18F and ^123I analogs?
Yes. Many dependent claims narrow X to ^18F or ^123I, with further dependent claims narrowing to a single isotope.
-
Is there coverage for cyclic embodiments?
Yes. Claim 3 explicitly requires a cyclic compound and fixes the index values and radionuclide narrowing via Claims 4–5.
-
Is there a specific substitution motif called out for ^123I?
Yes. Claims 26–27 require R1 = X--CH═CH-- with X = ^123I, along with fixed y and z values.
References (APA)
- United States Patent 5,808,146. (n.d.). Amino acid analogs radiolabeled with halogen radioisotopes. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
